A chimpanzee adenovirus-vectored single dose therapeutic vaccine for post kala azar dermal leishmaniasis. A chimpanzee adenovirus-vectored single dose therapeutic vaccine for post kala azar dermal leishmaniasis

Purpose: The goals of this study were to identify molecular patterns activated by the vaccine and potential predictors of clinical success. Overall design: Methods: Whole blood samples (2.5 ml) were collected into PAXGene tubes immediately prior to vaccination and at 1, 3 and 7 days post vaccination from 24 patients with persistent PKDL